Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q3 FY2025 Earnings Presentation
27 slides from Metropolis Healthcare's earnings presentation, Feb 4, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation
Ref: MHL/Sec&Legal/2024-25/93 February 04, 2025 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are e
Slide 2: Metropolis Healthcare Limited Q3FY25 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q3FY25 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Content
Performance Highlights 1 Financial performance indicators Segment, volume and other Operational KPIs 2 performance indicators Content Performance and Profit & Loss 3 Income Statement Company Updates Q3FY25 Metropolis 3.0 Metropolis 3.0 strategy Strategy 4 including network, digital, science and qual
Slide 5: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand 43+ years of trusted by clinicians, patients and 12% CAGR stakeholders. credible revenue experience Positively impact the lives of patients in growth in last their most anxious times a
Slide 6: Q3FY25 Financial Highlights
Q3FY25 Financial Highlights Revenue EBIDTA PAT INR 323 Cr INR 72 Cr INR 31 Cr 10.9% YoY 9.4% YoY 15.3% YoY Consistently delivering double digit growth in Revenues, EBIDTA & PAT Q3FY25 EBITDA Margins stood at 22.2% and PAT Margins were at 9.8% 4
Slide 7: 9MFY25 Financial Highlights
9MFY25 Financial Highlights Revenue EBIDTA PAT INR 986 Cr INR 241 Cr INR 116 Cr 12.5% YoY 17.8% YoY 26.5% YoY 9MFY25 revenue grew at 12.5% with EBIDTA growing faster than Revenues on account of high operating leverage Ongoing Investments are reaping benefits with increasing contribution to EBIDTA &
Slide 8: Q3FY25 Key Performance Indicators
Q3FY25 Key Performance Indicators • Revenue growth excl. the institutional business stood at ~13% i.e. B2C (15%) + B2B (10%) • Implemented micro-marketing strategies to enhance regional Patient Volume B2C Revenue B2B Revenue performance: • Introduced market-relevant pricing in 3.06 Mn INR 178 Cr key
Slide 9: Revenue growth on the back of increase in contribution from Truhealth & Specialty Segments
Revenue growth on the back of increase in contribution from Truhealth & Specialty Segments Patient Volume (in Mn) Test Volume (in Mn) Q3FY25 Segment Contribution 9.7% Routine 9% 6% 8% Routine 17% 19% 4% 8% 6% Semi-Special 3% Semi-Special 8.99 9.52 18.37 19.77 Specialty Specialty 13% 37% 27% TruHealt
Slide 10: Strong B2C revenue growth @ 15% YoY in Q3FY25
Strong B2C revenue growth @ 15% YoY in Q3FY25 o B2C contribution stood at 55%, an increase of 200 bps Y-o-Y o Patient volume grew by 5%, with a robust 10% increase in RPP (Revenue Per Patient), enabled by enhanced upselling 55% and value delivery (+213bps) +25% o Strong growth in Higher end-Specialt
Slide 11: B2B revenue growing by 10% YoY in Q3FY25
B2B revenue growing by 10% YoY in Q3FY25 – consistent double -digit growth, Third quarter in a row o Patient volume grew by 4%, with a notable 6% increase in RPP, driven by value-focused strategies and superior service delivery 36% o Dedicated focus on enhancing B2B service quality resulted in +21%
Slide 12: TruHealth Revenue grew @ 25% YoY
TruHealth Revenue grew @ 25% YoY o Margin-Accretive Growth: Prioritized high-value packages, achieving average realizations exceeding ₹2,500, reflecting a focus on delivering superior value to customers Growth o TruHealth Contribution Growth: Increased contribution from 14% in Q3FY24 to 17% in Q3FY2
Slide 13: Speciality Revenue grew @ 13% YoY
Speciality Revenue grew @ 13% YoY o Comprehensive Specialty Offering: Over 3,000 specialty tests and Specialty uniquely curated profiles across Gastroenterology, Nephrology, Neurology, Growth Oncology, Women & Child Health, Infectious Diseases, and Chronic Conditions. o Specialty Segment Growth: Ach
Slide 14: Network Expansion - on course to add labs & 2000 service centers by FY25
Network Expansion - on course to add 90 labs & 2000 service centers by FY25 Laboratory Network Service Network 199 209 4,450 Rationalization Period 4,150 175 3,675 841 +1,895 161 805 124 125 +84 2,731 2,555 3,134 704 754 119 Labs* 2,336 598 498 Centres 575 3,123 2,914 2,594 2,105 Rural 1,873 1,806 1
Slide 15: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Revenue Contribution Revenue Growth (MHL Categorisation) Focus 7.9% 11.8% 20% By Cities Focus Seeding Seeding 6.8% 8.1% 18% Others 62% Others 17.4% Revenue growth (ex of institutional business) Revenue Contribution Revenue Growth Presence in ~750 t
Slide 16: Q3 & 9MFY25 Consolidated Profit & Loss Statement
Q3 & 9MFY25 Consolidated Profit & Loss Statement Profit & Loss Statement (Rs. Crs.) Q3FY25 Q3FY24 Y-o-Y 9MFY25 9MFY24 Y-o-Y Revenue from Operations 323 291 10.9% 986 877 12.5% Costs 251 226 745 672 Reported EBIDTA 72 66 9.4% 241 205 17.8% Reported EBIDTA (%) 22.2% 22.5% -30 bps 24.5% 23.4% 110 bps D
Slide 17: Acquisition Update – Core Diagnostics
Acquisition Update – Core Diagnostics Core Diagnostics is India’s leading Oncology (cancer) specialty testing lab offering the most advanced testing in the industry. About Core Diagnostics Transaction Details High-end oncology lab based in Gurugram • Founded in 2012, Core is the leading Oncology (Ca
Slide 18: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 19: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 2 Strengthening the Core Expand to Adjacencies Expand market share in core and while Forging New Alliances newer geographies with a focus Expanding into adjacencies like on specialized and wellness complimenting radiology, allied test
Slide 20: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with SalesForce CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient Efficient 360-Degree Opportunity Case Relationship Reporting & Cross Enhanced Billing & Patie
Slide 21: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology 102 New Tests added in FY24 and Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven and
Slide 22: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener • 45% reduction in emissions intensity Well identified ESG Focus Areas and Tomorrow by 2030 e assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. Our first Business Responsibility
Slide 23: Key ESG Plans 2024-25
Key ESG Plans 2024-25 Emissions & Water & Waste Employee Risk Patient Privacy Energy Management Recruitment, Management and Electronic Development and Health Records Retention • Achieve 5% reduction • Career 2.0 Campaign to • Annual assessments of • 100% training on • Achieve 10% reduction in water
Slide 24: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive DSEU* (Delhi Skills MedEngage Too Shy to Ask(TSTA) Entrepreneurial healthcare Project University) • Integrating all UG and • TSTA Rural focusing on • 1000 TB patients to receive PG programs including adolescent reproductive and nutritional su
Slide 25: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Chairman Emeritus Promoter & Executive Chairperson Chief Executive Officer Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Kannan Alangadan Dr. Kirti Kazi Ishita Medhekar Dr. Punee
Slide 26: Recent Awards and Accolades
Recent Awards and Accolades Ameera Shah - Healthcare Icon/Leader of the Year Award at the ET Sept’24 Healthcare Excellence Awards 2024 Gold Award for Best Content Marketing & Bronze Award for Best Social Jul’24 Media Communication at E4M Health & Wellness Marketing Awards 2024 Gold Award - Diagnosti
Slide 27: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q3 FY2025 Earnings Presentation on 6ix